$OMIC
Singular Genomics Systems, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003743 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.22M $8.551M $6.201M
YoY Change 62.53% 403.59% 329.73%
% of Gross Profit
Research & Development $9.455M $8.910M $7.682M
YoY Change 62.46% 46.55% 44.26%
% of Gross Profit
Depreciation & Amortization $364.0K $303.0K $256.0K
YoY Change 82.91% 77.19% 82.86%
% of Gross Profit
Operating Expenses $19.67M $17.46M $13.88M
YoY Change -28.55% 124.49% 105.13%
Operating Profit -$17.46M -$13.88M
YoY Change 124.49% 105.13%
Interest Expense -$87.00K $234.0K $232.0K
YoY Change -59.15% 15.84% -1.28%
% of Operating Profit
Other Income/Expense, Net $0.00 -$7.000K $22.00K
YoY Change -100.0% -135.0%
Pretax Income -$19.76M -$17.61M -$37.48M
YoY Change -29.29% 122.0% 447.38%
Income Tax
% Of Pretax Income
Net Earnings -$19.76M -$17.61M -$37.48M
YoY Change -29.29% 122.0% 447.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$272.8K -$245.5K -$524.0K
COMMON SHARES
Basic Shares Outstanding 72.06M 71.56M
Diluted Shares Outstanding 71.72M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.2M $357.0M $371.7M
YoY Change
Cash & Equivalents $201.0M $239.3M $257.3M
Short-Term Investments $138.2M $117.8M $114.4M
Other Short-Term Assets $8.537M $7.214M $7.201M
YoY Change
Inventory $3.011M
Prepaid Expenses $3.715M $7.214M $7.201M
Receivables
Other Receivables
Total Short-Term Assets $347.8M $364.2M $378.9M
YoY Change 1161.33%
LONG-TERM ASSETS
Property, Plant & Equipment $6.072M $4.917M $3.434M
YoY Change 156.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.129M $1.000M $990.0K
YoY Change 1293.83%
Total Long-Term Assets $7.888M $6.604M $5.111M
YoY Change 169.12%
TOTAL ASSETS
Total Short-Term Assets $347.8M $364.2M $378.9M
Total Long-Term Assets $7.888M $6.604M $5.111M
Total Assets $355.6M $370.8M $384.0M
YoY Change 1065.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.348M $2.390M $2.698M
YoY Change 449.88%
Accrued Expenses $4.278M $3.443M $1.809M
YoY Change 168.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $3.473M
YoY Change -100.0%
Total Short-Term Liabilities $6.744M $5.991M $8.152M
YoY Change 82.76%
LONG-TERM LIABILITIES
Long-Term Debt $9.904M $9.868M $6.082M
YoY Change 16.94%
Other Long-Term Liabilities $2.827M $2.904M $3.168M
YoY Change 295.94%
Total Long-Term Liabilities $12.73M $12.77M $9.250M
YoY Change 38.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.744M $5.991M $8.152M
Total Long-Term Liabilities $12.73M $12.77M $9.250M
Total Liabilities $19.48M $18.76M $17.40M
YoY Change 51.29%
SHAREHOLDERS EQUITY
Retained Earnings -$151.9M -$132.1M -$114.5M
YoY Change 186.06%
Common Stock $7.000K $7.000K $7.000K
YoY Change 600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $336.2M $352.1M $366.6M
YoY Change
Total Liabilities & Shareholders Equity $355.6M $370.8M $384.0M
YoY Change 1065.98%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$19.76M -$17.61M -$37.48M
YoY Change -29.29% 122.0% 447.38%
Depreciation, Depletion And Amortization $364.0K $303.0K $256.0K
YoY Change 82.91% 77.19% 82.86%
Cash From Operating Activities -$15.70M -$10.98M -$15.84M
YoY Change 124.82% 64.68% 143.18%
INVESTING ACTIVITIES
Capital Expenditures -$1.770M -$1.621M -$963.0K
YoY Change 646.84% 123.9% 505.66%
Acquisitions
YoY Change
Other Investing Activities -$21.56M -$4.088M -$10.40M
YoY Change -372.95% -156.22% -237.58%
Cash From Investing Activities -$23.32M -$5.709M -$11.37M
YoY Change -404.5% -187.2% -253.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 810.0K -1.320M 239.2M
YoY Change 2354.55% 5639.13%
NET CHANGE
Cash From Operating Activities -15.70M -10.98M -15.84M
Cash From Investing Activities -23.32M -5.709M -11.37M
Cash From Financing Activities 810.0K -1.320M 239.2M
Net Change In Cash -38.21M -18.00M 212.0M
YoY Change -5482.25% 12669.5% 23688.44%
FREE CASH FLOW
Cash From Operating Activities -$15.70M -$10.98M -$15.84M
Capital Expenditures -$1.770M -$1.621M -$963.0K
Free Cash Flow -$13.93M -$9.355M -$14.87M
YoY Change 106.48% 57.47% 134.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Transition Report
DocumentTransitionReport
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity File Number
EntityFileNumber
001-40443
dei Entity Registrant Name
EntityRegistrantName
SINGULAR GENOMICS SYSTEMS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001850906
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2948451
dei Entity Address Address Line1
EntityAddressAddressLine1
10931 N. Torrey Pines Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #100
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
333-7830
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OMIC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72058523
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239263000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11688000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
117750000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
15231000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7214000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
652000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
364227000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27571000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4917000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2368000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
687000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
482000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2021Q3 us-gaap Assets
Assets
370831000
CY2020Q4 us-gaap Assets
Assets
30502000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2390000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
427000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3443000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1592000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
926000
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
451000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
158000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
294000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5991000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3690000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9868000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8469000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2904000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
714000
CY2021Q3 us-gaap Liabilities
Liabilities
18763000
CY2020Q4 us-gaap Liabilities
Liabilities
12873000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60272685
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71934170
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10816937
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
484202000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1552000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132136000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53125000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
352068000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-51555000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
370831000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30502000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8910000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6080000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15431000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8551000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1698000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18406000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4518000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
17461000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7778000
us-gaap Operating Expenses
OperatingExpenses
41606000
us-gaap Operating Expenses
OperatingExpenses
19949000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17461000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7778000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41606000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19949000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
91000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
76000
us-gaap Interest And Other Income
InterestAndOtherIncome
223000
us-gaap Interest And Other Income
InterestAndOtherIncome
444000
CY2021Q3 us-gaap Interest Expense
InterestExpense
234000
CY2020Q3 us-gaap Interest Expense
InterestExpense
202000
us-gaap Interest Expense
InterestExpense
654000
us-gaap Interest Expense
InterestExpense
503000
CY2021Q3 omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
0
omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
35199000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2180000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
405000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17611000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7933000
us-gaap Net Income Loss
NetIncomeLoss
-79011000
us-gaap Net Income Loss
NetIncomeLoss
-20033000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.91
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71721861
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10726496
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38553685
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10507732
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17611000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7933000
us-gaap Net Income Loss
NetIncomeLoss
-79011000
us-gaap Net Income Loss
NetIncomeLoss
-20033000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-22000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-22000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
24000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17633000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7939000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79033000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20009000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-51555000
CY2021Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
92000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
995000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1096000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-23921000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-73342000
CY2021Q2 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
69184000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
165699000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
237199000
CY2021Q2 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
230000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2341000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
49000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-37479000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
366578000
CY2021Q3 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
236000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2859000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17611000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
352068000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-24725000
CY2020Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
8000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
260000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
572000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6847000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
239000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-542000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-30269000
CY2020Q2 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
7000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-36275000
CY2020Q3 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
7000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
270000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7933000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-43933000
us-gaap Profit Loss
ProfitLoss
-79011000
us-gaap Profit Loss
ProfitLoss
-20033000
us-gaap Depreciation
Depreciation
769000
us-gaap Depreciation
Depreciation
441000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
94000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Share Based Compensation
ShareBasedCompensation
6296000
us-gaap Share Based Compensation
ShareBasedCompensation
770000
omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
35199000
omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2180000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1364000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
74000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
243000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
157000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6025000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
345000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
919000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1643000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5000
omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
1851000
omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
858000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-136000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
91000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
450000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
56000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36002000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17887000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
146070000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6086000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
26579000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
15049000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
8146000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3094000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1143000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-107536000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16350000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
237199000
omic Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
130500000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
15433000
omic Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10500000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7500000
omic Repayments Of Debt Principal And Issuance Costs In Connection With Refinancing
RepaymentsOfDebtPrincipalAndIssuanceCostsInConnectionWithRefinancing
10400000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3519000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
371318000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7487000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
227780000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5950000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12170000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5523000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239950000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11473000
us-gaap Interest Paid Net
InterestPaidNet
449000
us-gaap Interest Paid Net
InterestPaidNet
312000
omic Vesting Of Restricted Stock
VestingOfRestrictedStock
558000
omic Vesting Of Restricted Stock
VestingOfRestrictedStock
22000
omic Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
69184000
omic Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
0
omic Conversion Of Notes To Common Stock
ConversionOfNotesToCommonStock
165699000
omic Conversion Of Notes To Common Stock
ConversionOfNotesToCommonStock
0
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
319000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
66000
omic Warrants Issued In Connection With Issuance Of Long Term Debt
WarrantsIssuedInConnectionWithIssuanceOfLongTermDebt
0
omic Warrants Issued In Connection With Issuance Of Long Term Debt
WarrantsIssuedInConnectionWithIssuanceOfLongTermDebt
189000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
357000000.0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239263000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11688000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
687000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
482000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239950000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12170000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
117755000
CY2021Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-5000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
117750000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15214000
CY2020Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
17000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15231000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
85263000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
9559000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
32487000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
5672000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
117750000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
15231000
us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
three to five years
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6740000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3608000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1823000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1240000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4917000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2368000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2814000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1234000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
357000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
74000
CY2021Q3 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
70000
CY2020Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
44000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
202000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
240000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3443000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1592000
CY2019Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-09-01
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0065
omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.0550
CY2021Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
15000000.0
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-09-01
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0075
omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.0400
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
600000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
600000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10500000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
632000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
605000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
9868000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
9395000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
926000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9868000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8469000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
106000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
426000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
426000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1735000
CY2021Q3 omic Longtermdebtmaturitiesrepaymentsofprincipalinyearthreeandthereafter
Longtermdebtmaturitiesrepaymentsofprincipalinyearthreeandthereafter
9949000
CY2021Q3 omic Long Term Debt Maturities Repayments Of Principal Including Interest Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalIncludingInterestPayments
12642000
CY2021Q3 omic Interest And Final Payment Fee
InterestAndFinalPaymentFee
2142000
CY2021Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1400000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2021Q3 omic Lessee Operating Lease Liability Payments Due Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfFiscalYear
635000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6265000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7892000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6394000
CY2021Q3 omic Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
42122000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
63308000
CY2021Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
38826388
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
39020122
CY2021Q3 omic Temporary Equity Share Issued
TemporaryEquityShareIssued
38826388
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
38826388
CY2021Q3 omic Aggregate Liquidation Preference
AggregateLiquidationPreference
69500000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7274953
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M21D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7274953
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3111273
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.47
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5415875
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
102504
omic Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Forfeiture Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageForfeiturePrice
3.57
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4867847
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3373469
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M25D
CY2021Q3 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
1900
CY2021Q3 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
2585250
CY2020Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
141955
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2859000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6296000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
770000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7722
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0091
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0072
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13362130
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17611000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7933000
us-gaap Net Income Loss
NetIncomeLoss
-79011000
us-gaap Net Income Loss
NetIncomeLoss
-20033000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71721861
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10726496
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38553685
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10507732
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.91
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4867847
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45971395

Files In Submission

Name View Source Status
0000950170-21-003743-index-headers.html Edgar Link pending
0000950170-21-003743-index.html Edgar Link pending
0000950170-21-003743.txt Edgar Link pending
0000950170-21-003743-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omic-20210930.htm Edgar Link pending
omic-20210930.xsd Edgar Link pending
omic-20210930_cal.xml Edgar Link unprocessable
omic-20210930_def.xml Edgar Link unprocessable
omic-20210930_htm.xml Edgar Link completed
omic-20210930_lab.xml Edgar Link unprocessable
omic-20210930_pre.xml Edgar Link unprocessable
omic-ex10_1.htm Edgar Link pending
omic-ex31_1.htm Edgar Link pending
omic-ex31_2.htm Edgar Link pending
omic-ex32_1.htm Edgar Link pending
omic-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending